239 related articles for article (PubMed ID: 31728006)
1. Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein.
Khan E; Mishra SK; Mishra R; Mishra A; Kumar A
Sci Rep; 2019 Nov; 9(1):16872. PubMed ID: 31728006
[TBL] [Abstract][Full Text] [Related]
2. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington's disease (HD) and spinocerebellar ataxia (SCAs).
Khan E; Biswas S; Mishra SK; Mishra R; Samanta S; Mishra A; Tawani A; Kumar A
Biochimie; 2019 Aug; 163():21-32. PubMed ID: 31075282
[TBL] [Abstract][Full Text] [Related]
4. Structural Insights Reveal the Dynamics of the Repeating r(CAG) Transcript Found in Huntington's Disease (HD) and Spinocerebellar Ataxias (SCAs).
Tawani A; Kumar A
PLoS One; 2015; 10(7):e0131788. PubMed ID: 26148061
[TBL] [Abstract][Full Text] [Related]
5. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
[TBL] [Abstract][Full Text] [Related]
6. A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation.
Lazzeroni G; Benicchi T; Heitz F; Magnoni L; Diamanti D; Rossini L; Massai L; Federico C; Fecke W; Caricasole A; La Rosa S; Porcari V
J Biomol Screen; 2013 Oct; 18(9):984-96. PubMed ID: 23562876
[TBL] [Abstract][Full Text] [Related]
7. RNA FISH for detecting expanded repeats in human diseases.
Urbanek MO; Krzyzosiak WJ
Methods; 2016 Apr; 98():115-123. PubMed ID: 26615955
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
[TBL] [Abstract][Full Text] [Related]
9. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture.
Zhang X; Abels ER; Redzic JS; Margulis J; Finkbeiner S; Breakefield XO
Cell Mol Neurobiol; 2016 Apr; 36(3):459-70. PubMed ID: 26951563
[TBL] [Abstract][Full Text] [Related]
10. PolyQ-independent toxicity associated with novel translational products from CAG repeat expansions.
Rudich P; Watkins S; Lamitina T
PLoS One; 2020; 15(4):e0227464. PubMed ID: 32240172
[TBL] [Abstract][Full Text] [Related]
11. Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10.
Yang WY; Gao R; Southern M; Sarkar PS; Disney MD
Nat Commun; 2016 Jun; 7():11647. PubMed ID: 27248057
[TBL] [Abstract][Full Text] [Related]
12. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
[TBL] [Abstract][Full Text] [Related]
13. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
[TBL] [Abstract][Full Text] [Related]
14. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
Sugaya K
Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Small Molecules that Induce the Degradation of Huntingtin.
Tomoshige S; Nomura S; Ohgane K; Hashimoto Y; Ishikawa M
Angew Chem Int Ed Engl; 2017 Sep; 56(38):11530-11533. PubMed ID: 28703441
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.
Smith DL; Portier R; Woodman B; Hockly E; Mahal A; Klunk WE; Li XJ; Wanker E; Murray KD; Bates GP
Neurobiol Dis; 2001 Dec; 8(6):1017-26. PubMed ID: 11741397
[TBL] [Abstract][Full Text] [Related]
17. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.
Zhang X; Smith DL; Meriin AB; Engemann S; Russel DE; Roark M; Washington SL; Maxwell MM; Marsh JL; Thompson LM; Wanker EE; Young AB; Housman DE; Bates GP; Sherman MY; Kazantsev AG
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):892-7. PubMed ID: 15642944
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
19. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
20. Counting CAG repeats in the Huntington's disease gene by restriction endonuclease EcoP15I cleavage.
Möncke-Buchner E; Reich S; Mücke M; Reuter M; Messer W; Wanker EE; Krüger DH
Nucleic Acids Res; 2002 Aug; 30(16):e83. PubMed ID: 12177311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
